SCHEMBL21302003

SCHEMBL21302003

CC(C)(C)OC(=O)N1CCN(c2cccc(NCc3ccc(F)c(F)c3)c2N)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.45
ACHE P22303 2/20 0.44
MET P08581 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2C19 P33261 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
MAPK8 P45983 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
BACE1 P56817 2/20 0.40
CCNT1 O60563 1/20 0.40
DPP4 P27487 1/20 0.39
DNMT3A Q9Y6K1 1/20 0.39
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516382 1.00 KCNQ2 (0.45) KCNQ2ACHEMETSMN1; SMN2HTT
SCHEMBL21301987 0.92 P2RX7 (0.46) ACHEMETSMN1; SMN2HTTNPSR1
SCHEMBL30516387 0.92 P2RX7 (0.46) ACHEMETSMN1; SMN2HTTNPSR1
SCHEMBL22712832 0.90 CCNT1 (0.49) KCNQ2ACHEMETSMN1; SMN2HTT
SCHEMBL30516374 0.90 CCNT1 (0.49) KCNQ2ACHEMETSMN1; SMN2HTT
SCHEMBL4614667 0.89 ACHE (0.43) KCNQ2ACHEMETSMN1; SMN2HTT
SCHEMBL21301932 0.88 ACHE (0.47) KCNQ2ACHEMETSMN1; SMN2HTT
SCHEMBL30516377 0.88 ACHE (0.47) KCNQ2ACHEMETSMN1; SMN2HTT
SCHEMBL21301986 0.87 MAPK8 (0.47) KCNQ2ACHEMETSMN1; SMN2HTT
SCHEMBL30516368 0.87 MAPK8 (0.47) KCNQ2ACHEMETSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2024-05-14 US disclosed
EP-3755688-B1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S A (PL) 2023-06-14 EP disclosed
EP-3755688-B1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S A (PL) 2023-06-14 EP disclosed
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S.A. (PL) 2021-09-09 US disclosed
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S.A. (PL) 2021-09-09 US disclosed
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2021-06-15 US disclosed
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2021-06-15 US disclosed
CN-112041300-A Indole and benzimidazole derivatives as dual 5-HT2A and5-HT 6receptor antagonists 阿达梅德制药公司 2020-12-04 CN disclosed
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS ACADIA PHARMACEUTICALS INC. 2020-12-03 US disclosed
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS ACADIA PHARMACEUTICALS INC. 2020-12-03 US disclosed
WO-2019162306-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S.A. (PL) 2019-08-29 WO disclosed
EP-3530651-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed sp. z o.o. (PL) 2019-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR2C, HTR6 KCNQ2 452/4885ACHE 301/4885MET 1905/4885
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C KCNQ2 368/4885ACHE 287/4885MET 2102/4885
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C KCNQ2 368/4885ACHE 287/4885MET 2102/4885
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR2C, HTR6 KCNQ2 452/4885ACHE 301/4885MET 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.